Thus, this study aimed to investigate whether EZH2 and EZH1/2 inhibitors can inhibit the proliferation of HTLV-1-infected cells derived from patients with HAM and the excessive immune response seen in HAM in vitro and to examine their potential as novel therapeutic agents for HAM. The gene discussed is EZH1; the disease is tropical spastic paraparesis.